Physician profile
Renee Hernandez
NPI 1427152750
$5,102.44
in general payments reported to CMS, 2019-2025
29 companies · $1,103 in 2025
The $1,103 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $233 · 2021: $892 · 2022: $802 · 2023: $884 · 2024: $885 · 2025: $1,103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,872.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,871.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,079.55 | 2021-2024 | |
| Amgen INC. | $797.38 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $721.80 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $438.76 | 2021-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $207.65 | 2020-2025 | Hetlioz, Fanapt |
| Lilly USA, LLC | $202.24 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $171.56 | 2021-2025 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $160.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $150.47 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $149.57 | 2020-2024 | Xarelto |
| Glaxosmithkline, LLC. | $144.03 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.57 | 2022-2024 | |
| Otsuka America Pharmaceutical, INC. | $83.03 | 2023-2025 | Rexulti, Abilify Maintena |
| Ardelyx, INC. | $80.99 | 2022-2025 | Ibsrela |
| Horizon Therapeutics Plc | $78.18 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $76.07 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $66.16 | 2022-2024 | Linzess |
| Lundbeck LLC | $64.58 | 2022-2025 | Rexulti |
| Pfizer INC. | $52.15 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.36 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $44.50 | 2021-2023 | Eliquis, Camzyos |
| Nevro Corp. | $36.00 | 2022 | |
| Esperion Therapeutics, INC. | $32.25 | 2020-2022 | |
| Exact Sciences Corporation | $21.38 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $20.33 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.26 | 2022 | |
| Melinta Therapeutics, LLC | $14.15 | 2019 | |
| Phathom Pharmaceuticals, INC. | $13.64 | 2024 | Voquezna |
| Gilead Sciences, INC. | $13.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.